lonp1-in-2  (MedChemExpress)

Journal: Pharmaceutical Biology

Article Title: Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

doi: 10.1080/13880209.2025.2537125

Figure Lengend Snippet: Molecular docking of key components in WSTLZTD with LONP1. (A) Binding energy table of key components with LONP1. (B-H) Molecular docking patterns between LONP1 and Gastrodin, Imperatorin, Icariin, Luteolin, Psoralenoside, Quercetin and Astragaloside VI. In the docking diagrams: yellow stick models represent active molecules; cyan stick structures indicate amino acid residues on the LONP1 protein; dashed lines denote chemical bonds between the active compounds and amino acid residues.

Article Snippet: The selective LONP1 inhibitor LONP1-IN-2 (MCE, HY-153034) was utilized to validate the role of LONP1(Kingsley et al. ).

Techniques: Binding Assay

Journal: Pharmaceutical Biology

Article Title: Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

doi: 10.1080/13880209.2025.2537125

Figure Lengend Snippet: High-dose WSTLZTD may enhance BMSC osteogenic differentiation by alleviating BMDMs senescence via LONP1 and suppressing the cGAS/STING pathway in BMSCs. (A) WB analysis of LONP1, cGAS and STING protein levels in the femoral bone of mice. GAPDH was used as an internal control. (B) Quantitative analysis of LONP1, cGAS and STING protein expression using ImageJ software ( n = 3). (C) Representative IHC images of LONP1, cGAS and STING in femoral bone sections (scale bar: 20 μm). (D) Quantitative analysis of LONP1, cGAS and STING protein expression from IHC ( n = 3). (E) WB analysis of LONP1 protein levels in BMDMs across groups. GAPDH was used as an internal control. (F) Quantitative analysis of LONP1 expression in BMDMs using ImageJ software ( n = 3). (G) Immunofluorescence staining of cGAS and STING in BMSCs treated with BMDM-CM (scale bar: 10 μm). (H) Quantitative analysis of cGAS and STING protein expression using ImageJ software ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The selective LONP1 inhibitor LONP1-IN-2 (MCE, HY-153034) was utilized to validate the role of LONP1(Kingsley et al. ).

Techniques: Control, Expressing, Software, Immunofluorescence, Staining

Journal: Pharmaceutical Biology

Article Title: Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

doi: 10.1080/13880209.2025.2537125

Figure Lengend Snippet: Effects of WSTLZTD-containing serum on senescent RAW264.7 macrophages. (A) Cell viability of RAW264.7 cells treated with different concentrations of H 2 O 2 was assessed using the CCK-8 assay. (B) CCK-8 assay of senescent RAW264.7 cells treated with WSTLZTD-containing serum (low-, medium- and high-dose) ( n = 3). (C) β-Gal activity staining to evaluate senescence in RAW264.7 cells from control, model and WSTLZTD-containing serum-treated groups ( n = 3; scale bar: 100 μm). (D) Representative images of ALP and ARS staining in BMSCs treated with RAW-CM from control, model or high-dose WSTLZTD-containing serum groups ( n = 3; scale bar: 100 μm). (E) WB analysis of LONP1 protein levels in RAW264.7 cells across groups. GAPDH was used as an internal control. (F) Quantitative analysis of LONP1 expression using ImageJ software ( n = 3). (G) Immunofluorescence staining of cGAS and STING in BMSCs treated with RAW-CM from control, model or high-dose WSTLZTD-containing serum groups (scale bar: 10 μm). (H) Quantitative analysis of cGAS and STING expression using ImageJ software ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The selective LONP1 inhibitor LONP1-IN-2 (MCE, HY-153034) was utilized to validate the role of LONP1(Kingsley et al. ).

Techniques: CCK-8 Assay, Activity Assay, Staining, Control, Expressing, Software, Immunofluorescence

Journal: Pharmaceutical Biology

Article Title: Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

doi: 10.1080/13880209.2025.2537125

Figure Lengend Snippet: WSTLZTD may mediate macrophage senescence potentially through LONP1 and then regulate BMSC osteogenesis via cGAS/STING pathway. (A) The CCK-8 assay was employed to assess the viability of RAW264.7 cells and H 2 O 2 -induced senescent RAW264.7 cells, both subjected to treatment with the LONP1 inhibitor, LONP1-IN-2. (B) β-gal activity staining of RAW264.7 cells from the following groups: model, model + high-dose WSTLZTD-containing serum, model + vehicle serum + LONP1-IN-2 and model + high-dose WSTLZTD-containing serum + LONP1-IN-2 ( n = 3; scale bar: 100 μm). (C) Representative images of ALP and ARS staining in BMSCs treated with RAW-CM from each group ( n = 3; scale bar: 100 μm). (D) Immunofluorescence staining of cGAS and STING in BMSCs treated with RAW-CM from each group (scale bar: 10 μm). (E) Quantitative analysis of cGAS and STING protein expression using ImageJ software ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The selective LONP1 inhibitor LONP1-IN-2 (MCE, HY-153034) was utilized to validate the role of LONP1(Kingsley et al. ).

Techniques: CCK-8 Assay, Activity Assay, Staining, Immunofluorescence, Expressing, Software

Journal: Science Advances

Article Title: Epstein-Barr virus–driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation

doi: 10.1126/sciadv.adr8837

Figure Lengend Snippet: ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of LONP1 mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.

Article Snippet: LONP1-in-2 (HY-153034, MedChemExpress), a LONP1 selective inhibitor , was applied at a concentration of 0.5 μM for 12 hours, with DMSO used as the vehicle control.

Techniques: Infection, Western Blot, Expressing, Labeling, Control, Quantitative RT-PCR

Journal: Science Advances

Article Title: Epstein-Barr virus–driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation

doi: 10.1126/sciadv.adr8837

Figure Lengend Snippet: ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of LONP1 mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.

Article Snippet: LONP1-in-2 (HY-153034, MedChemExpress), a LONP1 selective inhibitor , was applied at a concentration of 0.5 μM for 12 hours, with DMSO used as the vehicle control.

Techniques: Infection, Western Blot, Expressing, Labeling, Control, Quantitative RT-PCR